Prelude Therapeutics (PRLD) Profit After Tax (2019 - 2026)

Prelude Therapeutics has disclosed Profit After Tax across 8 years of filings, most recently posting -$10.4 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$10.4 million, up 67.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$77.8 million (up 39.14% YoY), and the FY2025 annual result was -$99.5 million, up 21.76% from the prior year.
• Profit After Tax came in at -$10.4 million for Q1 2026 at Prelude Therapeutics, up from -$16.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$10.4 million in Q1 2026 to a low of -$34.7 million in Q2 2024.
• The 5-year median for Profit After Tax is -$30.0 million (2022), against an average of -$27.9 million.
• Across the five-year window, Profit After Tax sank 38.33% in 2022 and soared 67.63% in 2026, its largest moves.
• Prelude Therapeutics' Profit After Tax stood at -$28.6 million in 2022, then retreated by 15.48% to -$33.1 million in 2023, then increased by 13.13% to -$28.7 million in 2024, then jumped by 42.72% to -$16.5 million in 2025, then jumped by 36.9% to -$10.4 million in 2026.
• The last three Profit After Tax figures came in at -$10.4 million (Q1 2026), -$16.5 million (Q4 2025), and -$19.7 million (Q3 2025), per Business Quant data.